share_log

康方生物：致登記股東之通知信函及回條 - 2023年報之發佈通知

AKESO: Notification Letter and Reply Form to Registered Shareholders - Notice of Publication of 2023 Annual Report

Hong Kong Stock Exchange ·  Apr 29 10:39
Summary by Moomoo AI
康方生物科技（開曼）有限公司（「康方生物」或「公司」）於2024年4月29日發佈通知，宣布其2023年度報告已經發布。該報告提供中英文版本，可於香港聯合交易所有限公司（「香港交易所」）網站及康方生物官方網站上瀏覽。公司遵循2023年12月31日生效的無紙化上市機制及電子發佈公司通訊規定，已採用電子方式發佈公司通訊，包括董事報告、年度帳目、審計報告、中期報告、會議通知等。股東若遇到瀏覽或接收電子通訊困難，可向公司提出免費獲取印刷本的要求。此外，公司亦徵求股東提供電子郵件地址，以便發送需採取行動的公司通訊。股東可透過回條上的二維碼提供電郵地址，或選擇以印刷本形式接收公司通訊，並需於指示後一年內重新確認。
康方生物科技（開曼）有限公司（「康方生物」或「公司」）於2024年4月29日發佈通知，宣布其2023年度報告已經發布。該報告提供中英文版本，可於香港聯合交易所有限公司（「香港交易所」）網站及康方生物官方網站上瀏覽。公司遵循2023年12月31日生效的無紙化上市機制及電子發佈公司通訊規定，已採用電子方式發佈公司通訊，包括董事報告、年度帳目、審計報告、中期報告、會議通知等。股東若遇到瀏覽或接收電子通訊困難，可向公司提出免費獲取印刷本的要求。此外，公司亦徵求股東提供電子郵件地址，以便發送需採取行動的公司通訊。股東可透過回條上的二維碼提供電郵地址，或選擇以印刷本形式接收公司通訊，並需於指示後一年內重新確認。
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech” or the “Company”) issued a notice on 29 April 2024 announcing that its 2023 report has been issued. The report is available in Chinese and English and can be accessed on the website of the Hong Kong Stock Exchange Limited (“HKEx”) and on the official website of Kangfang Biotech. In compliance with the paperless listing mechanism and electronic company communications regulations effective December 31, 2023, the Company has adopted the electronic publication of its corporate communications, including Directors' Reports, Annual Accounts, Audit Reports, Interim Reports, Meeting Notices, etc. Shareholders who experience difficulties in accessing or receiving electronic communications may request the Company to obtain a free printed copy. In addition, the Company requests that shareholders provide an e-mail address for sending corporate communications that require action. Shareholders may provide an email address via the QR code on the return bar, or elect to receive the company's correspondence in printed form, subject to reconfirmation within one year of the instruction.
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech” or the “Company”) issued a notice on 29 April 2024 announcing that its 2023 report has been issued. The report is available in Chinese and English and can be accessed on the website of the Hong Kong Stock Exchange Limited (“HKEx”) and on the official website of Kangfang Biotech. In compliance with the paperless listing mechanism and electronic company communications regulations effective December 31, 2023, the Company has adopted the electronic publication of its corporate communications, including Directors' Reports, Annual Accounts, Audit Reports, Interim Reports, Meeting Notices, etc. Shareholders who experience difficulties in accessing or receiving electronic communications may request the Company to obtain a free printed copy. In addition, the Company requests that shareholders provide an e-mail address for sending corporate communications that require action. Shareholders may provide an email address via the QR code on the return bar, or elect to receive the company's correspondence in printed form, subject to reconfirmation within one year of the instruction.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more